Surface Oncology Stock Price. Everything You Need To Know About The Surface Oncology Stock!
Surface Oncology, Inc. is a clinical-stage immuno-oncology company headquartered in Cambridge, Massachusetts, with 60 full-time employees. The company went public on April 19, 2018.
Surface Oncology is focused on developing multiple antibody immunotherapy candidates that enhance the innate and adaptive immune responses, enabling an immunologic response and enhancing outcomes for patients with cancer. The company’s pipeline includes two wholly-owned clinical-stage programs targeting IL-27 (SRF388) and SRF114, a preclinical program focused on depleting tumor regulatory T cells through targeting CCR8.
In addition, Surface Oncology has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562). The company’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies.
As with any investment opportunity, it is important to conduct thorough research and analysis before investing in a stock. While Surface Oncology’s focus on immuno-oncology and novel cancer immunotherapies may be promising, it is important to keep in mind that investing in the stock market carries risks. Therefore, it is essential to make investment decisions based on your personal financial situation and investment goals.
Surface Oncology Stock Price. Everything You Need To Know About The Surface Oncology Stock! performance
- Employees 60
- Company HQ Cambridge
- Website https://www.surfaceoncology.com/
- Asset Type
- Market Capitalization 0
- Earnings Per Share
- Dividends Per Share
- Dividend Date
- Quarterly Earnings Growth
Surface Oncology is a promising biotechnology company that offers a unique opportunity for investors in Malaysia, Thailand, Indonesia, and Vietnam to dive into the healthcare sector. This innovative company focuses on developing breakthrough cancer immunotherapies that harness the power of the immune system to treat various types of cancer. By investing in Surface Oncology, retail investors in these countries can tap into the potential of cutting-edge medical advancements and contribute to the fight against cancer. To invest in Surface Oncology from Malaysia, Thailand, Indonesia, and Vietnam, investors can utilize the user-friendly investment platform provided by Zorion. With investment insights and educational resources available, retail investors can make informed decisions and broaden their investment knowledge.
